Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

Authors :: Simona Sestili
Agathe Boussaroque
Zoé Van de Wyngaert
Simona Lapusan
Annalisa Paviglianiti
Mara Memoli
Anne Banet
Mohamad Mohty
Clemence Mediavilla
Pierre Hirsch
Remy Dulery
Agnès Bonnin
Ramdane Belhocine
Antonio Bianchessi
Giorgia Battipaglia
Fabrizia Favale
Ollivier Legrand
Florent Malard
Anne Vekhoff
Eolia Brissot
Tounes Ledraa
Source :: Leukemia & Lymphoma. 62:419-427
Publication Year :: 2020
Publisher :: Informa UK Limited, 2020.
Abstract: We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (

Tools